Structure-Activity Relationship of the GPR55 Antagonist, CID16020046

  title={Structure-Activity Relationship of the GPR55 Antagonist, CID16020046},
  author={Andrew J. Brown and Irene Castellano-Pellicena and Carl P. Haslam and Paula Louise Nichols and Simon Dowell},
  pages={324 - 331}
Background/Aims: CID16020046 blocks the effect of the lipid lysophosphatidylinositol (LPI) at its receptor, GPR55. CID16020046 and another antagonist, ML193, have been used to investigate GPR55-mediated effects of LPI on cells, tissues, and in vivo. Here we describe the structure-activity relationship of CID16020046. Methods: Yeast or human cells were engineered to express GPR55 or control receptors. Cells were pretreated with a test agent before agonist challenge. Functional responses were… 

Figures from this paper

Lysophosphatidylinositol, an Endogenous Ligand for G Protein-Coupled Receptor 55, Has Anti-inflammatory Effects in Cultured Microglia
The results suggest that LysoPI may contribute to neuroprotection in pathological conditions such as brain injury or neurodegenerative diseases, through its suppressive role in the microglial inflammatory response.
GPR55 Receptor Activation by the N-Acyl Dopamine Family Lipids Induces Apoptosis in Cancer Cells via the Nitric Oxide Synthase (nNOS) Over-Stimulation
For these compounds, the mechanism of cell death induction differed from that published for anandamide and included neuronal nitric oxide synthase (nNOS) overstimulation with concomitant oxidative stress induction, and had an increased cytotoxicity for the cancer cells indicating a therapeutic potential.
A Guide to Targeting the Endocannabinoid System in Drug Design
The endocannabinoid system (ECS) is one of the most crucial systems in the human organism, exhibiting multi-purpose regulatory character. It is engaged in a vast array of physiological processes,


A Selective Antagonist Reveals a Potential Role of G Protein–Coupled Receptor 55 in Platelet and Endothelial Cell Function
CID16020046 concentration dependently inhibited LPI-induced activation of nuclear factor of activated T-cells, nuclear factor κ of activated B cells and serum response element, translocation of NFAT and NF-κB, and GPR55 internalization, suggesting a novel role for GPR 55 in platelet and endothelial cell function.
Treatment with the GPR55 antagonist CID16020046 increases neutrophil activation in mouse atherogenesis.
Results indicate that GPR55 is critical for the negative control of neutrophil activation in different phases of atherogenesis, and increased levels of the endocannabinoid and putative GPR 55 ligand anandamide (AEA) were found, suggesting its possible autocrine control of Neutrophil activity.
N-arachidonoyl glycine, another endogenous agonist of GPR55.
Pharmacology of GPR 55 in Yeast and Identification of GSK 494581 A as a Mixed-Activity Glycine Transporter Subtype 1 Inhibitor and GPR 55 Agonist
The characterization of GPR55 in the yeast Saccharomyces cerevisiae and in human embryonic kidney (HEK293) cells is presented, suggesting that the relatively low level of sequence identity between these orthologs translates to important functional differences in the ligand-binding site.
Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55.
New human G PR55 mRNA expression data are presented, providing supportive evidence of GPR55 expression in a vast array of tissues and cell types, and major recent developments in GPR 55 research are summarized.
The therapeutic potential of orphan GPCRs, GPR35 and GPR55
Reports that suggest that GPR35/CXCR8 and GPR55 may be promising therapeutic targets, with diverse physiological roles are reviewed.
2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55.
This study examined whether LPI is present in rat brain and compared the biological activities of various molecular species of LPI and related molecules using HEK293 cells expressing GPR55, finding that the level of biological activity of the 2-arachidonoyl species is markedly higher than those of others.
The GPR55 ligand L‐α‐lysophosphatidylinositol promotes RhoA‐dependent Ca2+ signaling and NFAT activation
It is found that treatment with LPI induces marked GPR55 internalization and stimulates a sustained, oscillatory Ca2+ release pathway, which is dependent on Gα13 and requires RhoA activation, and leads to the efficient activation of NFAT family transcription factors and their nuclear translocation.